These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 27267126)

  • 1. Nano-based strategies to overcome p-glycoprotein-mediated drug resistance.
    Niazi M; Zakeri-Milani P; Najafi Hajivar S; Soleymani Goloujeh M; Ghobakhlou N; Shahbazi Mojarrad J; Valizadeh H
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1021-33. PubMed ID: 27267126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revisiting the role of nanoparticles as modulators of drug resistance and metabolism in cancer.
    Gupta P; Jani KA; Yang DH; Sadoqi M; Squillante E; Chen ZS
    Expert Opin Drug Metab Toxicol; 2016; 12(3):281-9. PubMed ID: 26799671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression.
    Nobili S; Landini I; Mazzei T; Mini E
    Med Res Rev; 2012 Nov; 32(6):1220-62. PubMed ID: 21374643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives.
    Binkhathlan Z; Lavasanifar A
    Curr Cancer Drug Targets; 2013 Mar; 13(3):326-46. PubMed ID: 23369096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanotechnology applied to overcome tumor drug resistance.
    Gao Z; Zhang L; Sun Y
    J Control Release; 2012 Aug; 162(1):45-55. PubMed ID: 22698943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evading P-glycoprotein mediated-efflux chemoresistance using Solid Lipid Nanoparticles.
    Cavaco MC; Pereira C; Kreutzer B; Gouveia LF; Silva-Lima B; Brito AM; Videira M
    Eur J Pharm Biopharm; 2017 Jan; 110():76-84. PubMed ID: 27810470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapeutic potential of targeting ABC transporters to combat multi-drug resistance.
    Bugde P; Biswas R; Merien F; Lu J; Liu DX; Chen M; Zhou S; Li Y
    Expert Opin Ther Targets; 2017 May; 21(5):511-530. PubMed ID: 28335655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoparticle therapeutics: Technologies and methods for overcoming cancer.
    Cerqueira BB; Lasham A; Shelling AN; Al-Kassas R
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):140-51. PubMed ID: 26515260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Progress in the study of drug delivery system based on nanoparticles to overcome multi-drug resistance].
    Chen JN; Shen Q; Li SS
    Yao Xue Xue Bao; 2009 Apr; 44(4):333-7. PubMed ID: 19545047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomedicine to Deal With Cancer Cell Biology in Multi-Drug Resistance.
    Tekchandani P; Kurmi BD; Paliwal SR
    Mini Rev Med Chem; 2017; 17(18):1793-1810. PubMed ID: 26891930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tackling multidrug resistance mediated by efflux transporters in tumor-initiating cells.
    McIntosh K; Balch C; Tiwari AK
    Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):633-44. PubMed ID: 27116192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combating P-glycoprotein-mediated multidrug resistance using therapeutic nanoparticles.
    Zhang Q; Li F
    Curr Pharm Des; 2013; 19(37):6655-66. PubMed ID: 23621532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticle approaches to combating drug resistance.
    Moon JH; Moxley JW; Zhang P; Cui H
    Future Med Chem; 2015 Aug; 7(12):1503-10. PubMed ID: 26334205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells.
    Yadav S; van Vlerken LE; Little SR; Amiji MM
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):711-22. PubMed ID: 18618115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer.
    Abbasi M; Lavasanifar A; Uludag H
    Med Res Rev; 2013 Jan; 33(1):33-53. PubMed ID: 21523793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging advances in P-glycoprotein inhibitory nanomaterials for drug delivery.
    Kou L; Sun R; Bhutia YD; Yao Q; Chen R
    Expert Opin Drug Deliv; 2018 Sep; 15(9):869-879. PubMed ID: 30169976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The elimination of P-glycoprotein over-expressing cancer cells by antimicrobial cationic peptide NK-2: the unique way of multi-drug resistance modulation.
    Banković J; Andrä J; Todorović N; Podolski-Renić A; Milošević Z; Miljković D; Krause J; Ruždijić S; Tanić N; Pešić M
    Exp Cell Res; 2013 Apr; 319(7):1013-27. PubMed ID: 23298945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.